I am Associate Professor in Medical Physics at the Department of Physics, Stockholm University and the group research leader of the Stockholm University Medical Radiation Physics division which is affiliated to the Department of Oncology and Pathology at Karolinska Institutet. My main current research area concerns the biologically-optimized and adapted radiotherapy with respect to the adverse tumour response phenotypes as well as the quality of radiation, irradiation technique and fractionation regime.
2005 PhD in Radiation Physics at Umeå University, Umeå, Sweden
2005 Certification as Medical Physicist in Sweden
2010 Associate Professor (Docent), Medical Radiation Physics, Stockholm University, Sweden
PROJECT 1 - Biologically Optimised Adaptive RT
To combine the advantages of intensity modulated radiotherapy for photons, protons and light ions and molecular and functional imaging in order to exploit the potential to target precisely the adverse factors in the tumours and thus to tailor the treatment to the individual needs of the patients by developing quantitative methods for incorporating biological and functional information on adverse outcome treatment factors into the treatment planning and optimisation codes and the implementation of the computational models and algorithms for dose prescription and treatment adaptation in the clinical treatment planning system.
Part of this project is conducted within the EU-financed ARTFORCE project (www.cancerartforce.eu).
PROJECT 2 – Stereotactic Radiation Therapy – key factors and novel approaches
To analyse and quantify a multiobserver variability of target and organs at risk delineation and to evaluate the clinical potential impact of the differences for radiosurgery.
To analyse of the impact of the fractionation schedule in which the prescribed dose is delivered in Stereotactic Body Radiation Therapy (SBRT) on the tumour control probability for NSCLC depending on the intrinsic sensitivity of the cells to radiation and the oxygenation of the tumour and to explore the possibilities for the clinical validation of the theoretical findings.
PROJECT 3 – Brachytherapy – inverse planning, radiobiological evaluation and optimisation
The overall goal of this project is the optimisation of brachytherapy for cervical cancer in order to improve the treatment not only in clinical terms but also in a cost-effective manner.
The specific aims are focused on the comparison of different treatment planning approaches with the manual planning with respect to the dose to the target and the doses to the organs at risk. The comparison between inverse planning and manual optimization will also be performed with respect to radiobiological parameters combining the volumes and the doses received by either the target or the OARs with parameters describing the sensitivity to radiation of the various tissues involved.
The inverse planning techniques for brachytherapy will be further developed and optimised based on physical and radiobiological parameters.
PROJECT 4 – Risk for secondary cancers after photon and proton radiotherapy
The aim of this research project is the investigation of the risk for secondary cancers associated with modern radiotherapy implying not only new irradiation techniques like IMRT and proton therapy but also additional radiation exposure due to repeated imaging sessions. Three major directions of investigations will therefore be explored in this project.
One research direction will be concerned with the development, adaptation and validation of models and parameters to be used for risk predictions in radiotherapy. A second direction of research will be concerned with the optimisation of treatment approaches from the point of view of the associated risks for cancer induction. A third direction of investigation will deal with the estimation of risks from new forms of therapy employing protons which are currently being developed in Sweden and are estimated to be used on patients in a couple of years-time.
PROJECT 5 – Proton therapy - impact of variable RBE
To explore the impact of variable proton RBE on dose fractionation for clinically-relevant situations. A generic RBE=1.1 is generally used for isoeffect calculations, while experimental studies showed that proton RBE varies with tissue type, dose and LET.
Academic honors, awards and prizes
Member of the Council of the Centre for Radiation Protection Research (www.crpr-su.se)
Will intrafraction repair have negative consequences on extreme hypofractionation in prostate radiation therapy?
The British journal of radiology 2015;88(1056):20150588-
Cancer incidence and radiation therapy in Mozambique - a comparative study to Sweden
Acta oncologica (Stockholm, Sweden) 2014;53(5):712-5
Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: the influence of local oxygenation changes
Journal of radiation research 2014;55(5):902-11
Disregarding RBE variation in treatment plan comparison may lead to bias in favor of proton plans
Medical physics 2014;41(9):91706-
Dosimetric evaluation of manually and inversely optimized treatment planning for high dose rate brachytherapy of cervical cancer
Acta oncologica (Stockholm, Sweden) 2014;53(8):1012-8
Impact of dose and sensitivity heterogeneity on TCP
Computational and mathematical methods in medicine 2014;2014():182935-
Predicting the sensitivity to ion therapy based on the response to photon irradiation--experimental evidence and mathematical modelling
Anticancer research 2014;34(6):2801-6
Quantitative hypoxia imaging for treatment planning of radiotherapy
Advances in experimental medicine and biology 2014;812():143-8
Radiation burden from secondary doses to patients undergoing radiation therapy with photons and light ions and radiation doses from imaging modalities
Radiation protection dosimetry 2014;161(1-4):357-62
Survival and tumour control probability in tumours with heterogeneous oxygenation: a comparison between the linear-quadratic and the universal survival curve models for high doses
Acta oncologica (Stockholm, Sweden) 2014;53(8):1035-40
To fractionate or not to fractionate? That is the question for the radiosurgery of hypoxic tumors
Journal of neurosurgery 2014;121 Suppl():110-5
Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability
Radiation oncology (London, England) 2014;9():149-
Variability in target delineation for cavernous sinus meningioma and anaplastic astrocytoma in stereotactic radiosurgery with Leksell Gamma Knife Perfexion
Acta neurochirurgica 2014;156(12):2303-12
Dosimetric comparison between intra-cavitary breast brachytherapy techniques for accelerated partial breast irradiation and a novel stereotactic radiotherapy device for breast cancer: GammaPod™
Physics in medicine and biology 2013;58(13):4409-21
Impact of variable RBE on proton fractionation
Medical physics 2013;40(1):11705-
Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?
Anticancer research 2013;33(3):1009-11
Modelling tumour oxygenation, reoxygenation and implications on treatment outcome
Computational and mathematical methods in medicine 2013;2013():141087-
Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time
The British journal of radiology 2013;86(1025):20130015-
Radiobiological description of the LET dependence of the cell survival of oxic and anoxic cells irradiated by carbon ions
Journal of radiation research 2013;54(1):18-26
Radiobiological framework for the evaluation of stereotactic radiosurgery plans for invasive brain tumours
ISRN oncology 2013;2013():527251-
Reply to the comment on 'The influence of dose heterogeneity on tumour control probability in fractionated radiation therapy'
Physics in medicine and biology 2013;58(18):6591-2
Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery
Journal of contemporary brachytherapy 2012;4(4):205-12
Dose prescription and treatment planning based on FMISO-PET hypoxia
ACTA ONCOLOGICA 2012;51(2):222-30
Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients
Acta oncologica (Stockholm, Sweden) 2012;51(8):963-74
SECONDARY MALIGNANCIES FROM PROSTATE CANCER RADIATION TREATMENT: A RISK ANALYSIS OF THE INFLUENCE OF TARGET MARGINS AND FRACTIONATION PATTERNS
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2011;79(3):738-46
The influence of dose heterogeneity on tumour control probability in fractionated radiation therapy
PHYSICS IN MEDICINE AND BIOLOGY 2011;56(23):7585-600
Analytical Description of the LET Dependence of Cell Survival Using the Repairable-Conditionally Repairable Damage Model
RADIATION RESEARCH 2010;174(4):517-25
Dose prescription and optimisation based on tumour hypoxia
ACTA ONCOLOGICA 2009;48(8):1181-92
QUANTIFYING TUMOUR HYPOXIA BY PET IMAGING - A THEORETICAL ANALYSIS
OXYGEN TRANSPORT TO TISSUE XXX 2009;:267-72
THE RELATIONSHIP BETWEEN VASCULAR OXYGEN DISTRIBUTION AND TISSUE OXYGENATION
OXYGEN TRANSPORT TO TISSUE XXX 2009;:255-60
Treatment modelling: The influence of micro-environmental conditions
ACTA ONCOLOGICA 2008;47(5):896-905
Vascular oxygen content and the tissue oxygenation--a theoretical analysis
Medical physics 2008;35(2):539-45
What is the clinically relevant relative biologic effectiveness? A warning for fractionated treatments with high linear energy transfer radiation
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2008;70(3):867-74
What is the clinically relevant relative biologic effectiveness? A warning for fractionated treatments with high linear energy transfer radiation: In regard to Dasu and Toma-Dasu. (Int J Radiat Oncol Biol Phys 2008;70 : 867-874) - Response
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2008;70(5):1614-1615
Theoretical simulation of tumour hypoxia measurements
OXYGEN TRANSPORT TO TISSUE XXVII 2006;:369-74
Theoretical simulation of tumour oxygenation--practical applications
Advances in experimental medicine and biology 2006;578():357-62
Conversion of polarographic electrode measurements - a computer based approach
PHYSICS IN MEDICINE AND BIOLOGY 2005;50(19):4581-91
Dose-effect models for risk - relationship to cell survival parameters
ACTA ONCOLOGICA 2005;44(8):829-35
The effects of hypoxia on the theoretical modelling of tumour control probability
ACTA ONCOLOGICA 2005;44(6):563-71
The use of risk estimation models for the induction of secondary cancers following radiotherapy
ACTA ONCOLOGICA 2005;44(4):339-47
The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiation
PHYSICS IN MEDICINE AND BIOLOGY 2004;49(19):4463-75
Computer simulation of oxygen microelectrode measurements in tissues
OXYGEN TRANSPORT TO TISSUE VOLUME XXIII 2003;:157-61
Should single or distributed parameters be used to explain the steepness of tumour control probability curves?
PHYSICS IN MEDICINE AND BIOLOGY 2003;48(3):387-97
Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia
PHYSICS IN MEDICINE AND BIOLOGY 2003;48(17):2829-42
Theoretical simulation of oxygen tension measurement in the tissue using a microelectrode: II. Simulated measurements in tissues
RADIOTHERAPY AND ONCOLOGY 2002;64(1):109-18
Theoretical simulation of oxygen tension measurement in tissues using a microelectrode: I. The response function of the electrode
PHYSIOLOGICAL MEASUREMENT 2001;22(4):713-25
Comments on 'Standard effective doses for proliferative tumours'
PHYSICS IN MEDICINE AND BIOLOGY 2000;45(10):L45-50